Effect of cimetidine and ranitidine on carbamazepine and sodium valproate pharmacokinetics.
The pharmacokinetics of a single oral dose (400 mg) of carbamazepine and sodium valproate were compared in peptic ulcer patients before and after four weeks of a therapeutic course of either cimetidine (1 g/day, n = 6 subjects) or ranitidine (300 mg/day, n = 6 subjects). There was a small (up to 20%) but statistically significant decrease in oral clearance of carbamazepine after cimetidine treatment. A similar fall in sodium valproate clearance in five cimetidine-treated patients was accompanied by a significantly prolonged elimination half-life. No such trends were demonstrated during ranitidine treatment. Since both anticonvulsants are partly metabolized by hepatic mixed function oxidases, an inhibition by cimetidine at this level may be responsible for the observed impairment of clearance. Thus a potentially important clinical interaction may occur in patients taking anticonvulsants and cimetidine concurrently.
D002220:Carbamazepine / Q000378:metabolism*; D002927:Cimetidine / Q000494:pharmacology*; D004347:Drug Interactions; D005260:Female; D006801:Humans; D007700:Kinetics; D008297:Male; D006899:Mixed Function Oxygenases / Q000037:antagonists & inhibitors; D011899:Ranitidine / Q000494:pharmacology*; D014635:Valproic Acid / Q000378:metabolism*
D002220:Carbamazepine; D014635:Valproic Acid; D002927:Cimetidine; D011899:Ranitidine; D006899:Mixed Function Oxygenases